Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis (NCT06950385) | Clinical Trial Compass
RecruitingPhase 3
Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis
United States168 participantsStarted 2025-07-18
Plain-language summary
The main goal of this clinical trial is to learn if the drug eRapa works to slow down the progression of disease in patients diagnosed with Familial Adenomatous Polyposis (FAP). Researchers will compare eRapa to Placebo. The questions to be answered by this trial are:
* Does taking eRapa help to slow down the progression of the disease in patients with FAP?
* Is eRapa a safe treatment for patients diagnosed with FAP?
* What is the effect of eRapa on the number of polyps found in GI tract of patients diagnosed with FAP?
* How does treatment with eRapa affect a patient's quality of life?
Participants will:
* Take eRapa or placebo once per day every other week until disease progresses (gets worse), stops taking part in the trial or dies.
* Visit the clinic once every 3 months for check ups and tests.
* Have an endoscopy at the start of the trial and then every 6 months to check on whether the disease is getting better or worse.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Participant must be ≥18 years of age inclusive.
✓. Participant must have documented FAP, confirmed by adenomatous polyposis coli genotype mutation testing.
✓. Participant must have at least 1 of the following high-risk features: \>100 polyps but ≤500 polyps in the colon, or ≥10 polyps in the retained rectum/sigmoid or ileal pouch (≥3 mm in size), or Spigelman stage 3 or 4 with at least 1 polyp ≥10 mm to be removed at baseline or on endoscopy performed within 18 months of screening.
✓. Contraceptive use by participants or participant partners until at at least 12 weeks after stopping study treatment.
✓. Agree not to donate gametes for the purpose of reproduction until at at least 12 weeks after stopping study treatment.
✓. Willing to undergo endoscopic evaluation.
Exclusion criteria
✕. Participant has unresected or incompletely resected high-grade dysplasia or cancer within the duodenum, colon, rectum, or ileal pouch at screening endoscopy.
✕. Participant has any polyps ≥8 mm in the duodenum, colon, rectum, or ileal pouch remaining after screening endoscopy (polyps ≥8 mm are to be resected during screening endoscopy).
What they're measuring
1
Progression-free survival (PFS) in high-risk patients with FAP treated with eRapa versus placebo.
✕. Participant has had surgery within 6 weeks of the trial.
✕. Participant has active malignancy or history of malignancy diagnosed within 24 months of first dose of trial intervention.
✕. Participant has a history of, or currently has, an acquired or primary (congenital) immunodeficiency.
✕. Participant has active and clinically significant tuberculosis (positive Quantiferon Gold test), bacterial, fungal, or viral infection, including human immunodeficiency virus (HIV).
✕. Participant has any medical or social condition that, in the opinion of the Investigator, might increase participant risk if enrolled, prevent participant compliance to trial procedures, or present an unacceptable confound to safety or clinical trial data.